Comprehensive NeuroScience Announces New Company Name
Comprehensive NeuroScience
is pleased to announce its plans to roll out the new company name,
Comprehensive Clinical Development
. Under its new name, Comprehensive Clinical Development will continue to deliver CRO services in partnership with quality sponsors.
Comprehensive Clinical Development offers full-service capabilities and therapeutic expertise in numerous indications, including, but not limited to, CNS, dermatology, diabetes, infectious disease, obesity, and postmenopausal women, and collects early efficacy data across these populations.
Offering CRO services both of developmental and clinical conduct, Comprehensive Clinical Development leverages the diversity of its service networks to provide biopharmaceutical clients with exceptional quality and cost-effective trial management. Along with early and late phase site clinical conduct, Comprehensive Clinical Development provides a full range of services from protocol writing through final clinical study reporting.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
